Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma
Status:
Withdrawn
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This study is being conducted by Brian Poligone, MD PhD. The purpose of this study is to
determine safety, effectiveness, and tolerability of two topical therapies, imiquimod and
fluocinonide, for patients with early stage Cutaneous T-cell Lymphoma (CTCL).
Phase:
N/A
Details
Lead Sponsor:
Rochester General Hospital
Collaborators:
Bausch Health Americas, Inc. Rochester Skin Lymphoma Medical Group, PLLC Valeant Pharmaceuticals International, Inc.